Polypharmacy prescribing guidance - draft: consultation

Antihypertensive drug therapy

BP control (<140/90mmHg)

Adults 60 years or older with primary HTN

Total mortality

Mean 3.8 years

100

380

UE ^[323]

Antihypertensive drug therapy

BP control (<140/90mmHg)

Adults 60 years or older with primary HTN

CV mortality and morbidity

Mean 3.7 years

27

100

UE 323

Antihypertensive drug therapy

BP control (<140/90mmHg)

Adults 60 years or older with primary HTN

Cerebrovascular mortality and morbidity

Mean 3.7 years

56

207

UE 323

Antihypertensive drug therapy

BP control (<140/90mmHg)

Adults 60 years or older with primary HTN

CHD mortality and morbidity

Mean 2.9 years

91

264

UE 323

Antihypertensive drug therapy

BP control (<140/90mmHg)

Healthy ambulatory adults 60 to 79 years with HTN

Total mortality

Mean 4.4 years

72

317

UE 323

Antihypertensive drug therapy

BP control (<140/90mmHg)

Healthy ambulatory adults 60 to 79 years with HTN

CV mortality and morbidity

Mean 4.2 years

27

113

UE 323

Antihypertensive drug therapy

BP control (<140/90mmHg)

Healthy ambulatory adults 60-79 years with HTN

Cerebrovascular mortality and morbidity

Mean 4.2 years

59

248

UE 323

Antihypertensive drug therapy

BP control (<140/90mmHg)

Healthy ambulatory adults 60-79 years with HTN

CHD mortality and morbidity

Mean 4.2 years

91

382

UE 323

Antihypertensive drug therapy

BP control (<140/90mmHg)

Healthy ambulatory adults 80 years or older with HTN

CV mortality and morbidity

Mean 2.2 years

35

77

UE 323

Antihypertensive drug therapy

BP control (<140/90mmHg)

Healthy ambulatory adults 80 years or older with HTN

Cerebrovascular mortality and morbidity

Mean 2.2 years

59

148

UE 323

Antihypertensive drug therapy

BP control (<140/90mmHg)

Healthy ambulatory adults 80 years or older with HTN

Total mortality

Mean 2.3 years

NS

NS

UE 323

Antihypertensive drug therapy

BP control (<140/90mmHg)

Healthy ambulatory adults 80 years or older with HTN

CHD mortality and morbidity

Mean 2.5 years

NS

NS

UE 323

Antihypertensive drug therapy

BP control (<140/90mmHg)

Adults 18-59 years, mean age 50, with primary HTN (mild-moderate systolic or diastolic HTN)

Total CV mortality and morbidity

Mean 5 years

112

560

UE ^[324]

Antihypertensive drug therapy

BP control (<140/90mmHg)

Adults 18-59 years, mean age 50, with primary HTN (mild-moderate systolic or diastolic HTN)

Cerebrovascular mortality and morbidity

Mean 5 years

143

715

UE 324

Low-dose thiazide

Adults, mean age 61 years, with primary HTN

Total mortality

Mean 4.1 years

83

340

UE ^[325]

Low-dose thiazide

Adults, mean age 61 years, with primary HTN

Total stroke

Mean 4.1 years

50

205

UE 325

Low-dose thiazide

Adults, mean age 61 years, with primary HTN

Total CHD

Mean 4.1 years

91

373

UE 325

Low-dose thiazide

Adults, mean age 61 years, with primary HTN

Total CV

events

Mean 4.1 years

26

107

UE 325

First-line beta-blocker

Adults, mean age 56 years, with primary HTN

Total stroke

Mean 5.3 years

167

885

UE 325

First-line beta-blocker

Adults, mean age 56 years, with primary HTN

Total CV events

Mean 5.3 years

125

663

UE 325

First-line beta-blocker

Adults, mean age 56 years, with primary HTN

Total mortality

Mean 5.3 years

NS

NS

UE 325

First-line beta-blocker

Adults, mean age 56 years, with primary HTN

Total CHD

Mean 4.1 years

NS

NS

UE 325

First-line angiotensin converting enzyme inhibitor

Adults, mean age 67 years, with primary HTN

Total mortality

Mean 4.9 years

43

211

UE 325

First-line angiotensin converting enzyme inhibitor

Adults, mean age 67 years, with primary HTN

Total stroke

Mean 4.9 years

48

235

UE 325

First-line angiotensin converting enzyme inhibitor

Adults, mean age 67 years, with primary HTN

Total CHD

Mean 4.9 years

40

196

UE 325

First-line angiotensin converting enzyme inhibitor

Adults, mean age 67 years, with primary HTN

Total CV events

Mean 4.9 years

21

103

UE 325

First-line calcium channel blocker

Adults, mean age 70 years, with primary HTN

Total stroke

Mean 2.5 years

67

168

UE 325

First-line calcium channel blocker

Adults, mean age 70 years, with primary HTN

Total CV events

Mean 2.5 years

42

105

UE 325

First-line calcium channel blocker

Adults, mean age 70 years, with primary HTN

Total mortality

Mean 2.5 years

NS

NS

UE 325

First-line calcium channel blocker

Adults, mean age 70 years, with primary HTN

Total CHD

Mean 2.5 years

NS

NS

UE 325

ACE inhibitor (enalapril 2.5 to 40mg/day, up-titrated as tolerated)

Adults, mean age 70 years, with severe HF, NYHA class IV.

Comorbidities included CHD, previous MI, hypertension and diabetes

Prevent one death from any cause

188 days (mean follow-up)

7

3

PG ^[326]

ACE inhibitor (enalapril 2.5 to 20mg/day, up-titrated as tolerated)

Adults with HF, mean age 61 years, approximately 80% male. NYHA class I – IV, less than 2% NYHA Class IV; and LVEF ≤0.35

Prevent one death from any cause

41.4 months (mean follow-up).

22

76

PG ^[327]

ACE inhibitor (enalapril 2.5 to 20mg/day, up-titrated as tolerated)

Adults with HF and CKD, mean age 64 years, approximately 75% male. NYHA class I - IV and LVEF ≤0.35 and eGFR <60 mL/ min/1.73m²

Prevent one death from any cause

41.4 months (mean follow-up).

29

101

PG ^[328]

ACE inhibitor (enalapril 2.5 to 20mg/day, up-titrated as tolerated)

Adults with asymptomatic HF, mean age 60 years, approximately 75% male. NYHA class I and LVEF ≤0.35

Prevent one death from any cause

34 months (mean follow-up)

88

251

PG ^[329]

Valsartan and sacubitril

8,399 adults, age not reported, with HFrEF

Mortality, all-cause

Not reported

28

NC

UE ^[330]

Valsartan and sacubitril

8,399 adults, age not reported, with HFrEF

Mortality, CV causes

Not reported

31

NC

UE 330

Valsartan and sacubitril

8,399 adults, age not reported, with HFrEF

CV death/HF hospitalisation

Not reported

21

NC

UE 330

Valsartan and sacubitril

8,399 adults, age not reported, with HFrEF

Hospitalisation for HF

Not reported

28

NC

UE 330

Valsartan and sacubitril

8,399 adults, age not reported, with HFrEF

Hospitalisation, all-cause

Not reported

89

NC

UE 330

Valsartan and sacubitril

8,399 adults, age not reported, with HFrEF

Hospitalisation due to HF

Not reported

45

NC

UE 330

Valsartan and sacubitril

8,399 adults, age not reported, with HFrEF

Emergency department visit for HF

Not reported

14

NC

UE 330

Spironolactone 25mg daily

Adults, mean age 65 years, with NYHA class IV HF in the 6 months prior to enrolment, but were NYHA class III or IV at the time of enrolment

Prevent one death (all causes)

Mean 2 years

9

18

PG ^[331]

Beta-blocker (bisoprolol titrated to target dose of 10mg/day)

Adults, mean age 61 years, with moderate to severe HF NYHA class III or IV and LVEF ≤0.35

Prevent one death (all causes)

Mean 1.3 years

18

24

PG ^[332]

Warfarin (target INR 2 - 3)

Adults aged ≥75 years, mean age 81.5 years, with AF. 73% had a CHADS2 score of 1-2

First occurrence of fatal or non-fatal disabling stroke, other intracranial haemorrhage or clinically significant arterial embolism

2.7 years (mean follow-up)

20

54

PG ^[333]

Aspirin

Adults, 19-94 years with HTN or coronary risk factors without overt diseases. No history of occlusive disease

Primary prevention of serious vascular event (MI, stroke or vascular death)

Mean 5.8 years

246

1428

PG ^[334]

Aspirin or other antiplatelet

Adults with CVD with history of stroke or TIA

Secondary prevention of serious vascular event (non-fatal MI, non-fatal stroke or vascular death)

29-31 months

28-40

68-94

PG ^{[335] [336]}

Antiplatelet

Adults at high risk of CV events (previous MI, acute MI, previous stroke/ TIA, and other high risk, excluding acute stroke)

Secondary prevention of serious vascular event (non-fatal MI, non-fatal stroke or vascular death)

26 months

15

32

PG 337

Aspirin & dipyridamole

Adults with CVD, mean age 54 years, with arterial vascular disease (coronary artery disease, MI, angina, retinopathy, nephropathy, PAD, stroke, TIA, amaurosis fugax)

Secondary prevention of vascular event (non-fatal MI, non-fatal stroke or vascular death)

30 months

25

163

PG ^[337]

GLP1-RA in addition to metformin

People with T2DM taking metformin

Developing 3P- Major adverse CV events

Median follow-up range 1.3-5.4 years

40

NC

NE

^[338]

GLP1-RA in addition to metformin

People with T2DM taking metformin

Risk of CV death

Median follow-up range 1.3-5.4 years

112

NC

NE 338

GLP1-RA in addition to metformin

People with T2DM taking metformin

All-cause mortality

Median follow-up range 1.3-5.4 years

77

NC

NE 338

GLP1-RA in addition to metformin

People with T2DM taking metformin

Risk of developing all stroke

Median follow-up range 1.3-5.4 years

125

NC

NE 338

GLP1-RA in addition to metformin

People with T2DM taking metformin

Non-fatal stroke

Median follow-up range 1.3-5.4 years

167

NC

NE 338

GLP1-RA in addition to metformin

People with T2DM taking metformin

Risk of renal composite outcome

Median follow-up range 1.3-5.4 years

35

NC

NE 338

GLP1-RA in addition to metformin

People with T2DM taking metformin

End-stage renal disease

Median follow-up range 1.3-5.4 years

500

NC

NE 338

GLP1-RA in addition to metformin

People with T2DM taking metformin

Risk of developing macro albuminuria

Median follow-up range 1.3-5.4 years

42

NC

NE 338

GLP-1 RA

liraglutide, lixisenatide, semaglutide, exenatide dulaglutide,

oral semaglutide

Adults approx. 63.6 years, 39% female, 68% with CVD, 100% with T2DM

Major adverse CV events

Mean 2.98 years

NS

NS

NE

^[339]

GLP-1 RA

liraglutide, lixisenatide, semaglutide, exenatide dulaglutide,

oral semaglutide

Adults approx. 63.6 years, 39% female, 68% with CVD, 100% with T2DM

CV deaths

Mean 2.98 years

NS

NS

NE

339

GLP-1 RA

liraglutide, lixisenatide, semaglutide, exenatide dulaglutide,

oral semaglutide

Adults approx. 63.6 years, 39% female, 68% with CVD, 100% with T2DM

Hospitalisation for HF

Mean 2.98 years

111

331

NE

339

GLP1-RA liraglutide, semaglutide, exenatide, albiglutide, dulaglutide,

oral semaglutide

Adults approx. 62.8 years, with duration of diabetes 12 (+/- 0.8) years

Major adverse CV events

Mean 2.88 years

77

222

NE

^[340]

Semaglutide

Adults approx. 63.4 years, with duration of diabetes 10.6 (+/- 4) years

Major adverse CV events

Mean 2.77 years

43

119

NE 340

Empagliflozin

Adults with T2DM and various baseline degrees of CV risk

All-cause death^**

NR

83

NC

UE

^[341]

Empagliflozin

Adults with T2DM and various baseline degrees of CV risk

CV death

NR

77

NC

UE 341

Empagliflozin

Adults with T2DM and various baseline degrees of CV risk

Hospitalisation for HF

NR

72

NC

UE 341

Empagliflozin

Adults with T2DM and various baseline degrees of CV risk

All-cause hospitalisation

NR

35

NC

UE 341

Empagliflozin

Adults with T2DM and various baseline degrees of CV risk

Investigator-reported heart failure*

NR

56

NC

UE 341

Empagliflozin

Adults with T2DM and various baseline degrees of CV risk

Incident or worsening nephropathy

NR

16

NC

UE 341

Empagliflozin

Adults with T2DM and various baseline degrees of CV risk

Total, non-serious adverse effects

NR

21

NC

UE 341

Empagliflozin

Adults with T2DM and various baseline degrees of CV risk

Reduction in hypoglycaemia events

NR

5

NC

UE 341

Empagliflozin

Adults with T2DM and various baseline degrees of CV risk

Total, non-serious adverse events

NR

18

NC

UE 341

Empagliflozin

Adults T2DM and CVD ≥ 65 years

Composite outcome death from CV causes, nonfatal MI

NR

24

NC

UE 341

Empagliflozin

Asian adults T2DM and CVD

Composite outcome death from CV causes, nonfatal MI

NR

29

NC

UE 341

Empagliflozin

Hispanic/Latino adults T2DM and CVD

Composite outcome death from CV causes, nonfatal MI

NR

24

NC

UE 341

Empagliflozin

Adults T2DM and CVD living in Latin America

Composite outcome death from CV causes, nonfatal MI

NR

22

NC

UE 341

Empagliflozin

Adults T2DM and CVD with HbA1c <8.5%

Composite outcome death from CV causes, nonfatal MI

NR

34

NC

UE 341

Empagliflozin

Adults T2DM and CVD with BMI <30

Composite outcome death from CV causes, nonfatal MI

NR

30

NC

UE 341

Empagliflozin

Adults T2DM and CVD with eGFR 60-90 mL/min/1.73m²

Composite outcome death from CV causes, nonfatal MI

NR

40

NC

UE 341

Empagliflozin

Adults T2DM and CVD not taking Metformin

Composite outcome death from CV causes, nonfatal MI

NR

27

NC

UE 341

Empagliflozin

Adults T2DM and CVD not taking insulin

Composite outcome death from CV causes, nonfatal MI

NR

41

NC

UE 341

Empagliflozin

Adults T2DM and CVD not taking thiazolidinediones

Composite outcome death from CV causes, nonfatal MI

NR

58

NC

UE 341

Empagliflozin

Adults T2DM and CVD not taking DPP-4 inhibitor

Composite outcome death from CV causes, nonfatal MI

NR

47

NC

UE 341

SGLT-2i and Sulfonylureas

Adults with T2DM

Risk of hypoglycaemia

24 weeks or less (mean 16)

NR

NC

UE

^[342]

SGLT-2i and Sulfonylureas

Adults with T2DM

Risk of hypoglycaemia

25-48 weeks (mean 48)

NR

NC

UE 342

SGLT-2i and Sulfonylureas

Adults with T2DM

Risk of hypoglycaemia

≥ 48 weeks (mean 62)

NR

NC

UE 342

SGLT-2i

Patients ≥18 years, T2DM and either have established CVD or had risk factors for CVD

Composite CV outcome

3.08 years

167

514

UE

^[343]

SGLT-2i

Patients ≥18 years, T2DM, and either have established CVD or had risk factors for CVD

All-cause mortality

3.08 years

143

440

UE 343

SGLT-2i

Patients ≥18 years, T2DM, and either have established CVD or had risk factors for CVD

Death from CV causes alone

3.08 years

250

770

UE 343

SGLT-2i

Patients ≥18 years, T2DM, and either have established CVD or had risk factors for CVD

Death from CV causes alone in patients with eGFR < 60 mL/min/1.73m²

3.08 years

65

200

UE 343

SGLT-2i

Patients ≥18 years, T2DM, and either have established CVD or had risk factors for CVD

Heart failure hospitalisations

3.08 years

91

280

UE 343

SGLT-2i

Patients ≥18 years, T2DM, and either have established CVD or had risk factors for CVD

Composite renal outcome

3.08 years

67

206

UE 343

SGLT-2i

Patients ≥18 years, T2DM, and either have established CVD or had risk factors for CVD

Composite renal outcome in patients with eGFR < 60 mL/min/1.73 m²

3.08 years

37

114

UE 343

SGLT-2i

Patients ≥18 years, T2DM, and either have established CVD or had risk factors for CVD

Progression of albuminuria

3.08 years

27*

83

UE 343

SGLT-2i in monotherapy or add-on therapy with any approved agent (canagliflozin, dapagliflozin, empagliflozin or ertugliflozin)

T2DM patients aged 18 years or older, mean age 63.1-64.4 years. Patients had any established CVD, multiple CV risk factors and/or renal impairment

All-cause mortality

Median follow-up range 2.4-4.2 years

58

NC

UE ^[344]

SGLT-2i in monotherapy or add-on therapy with any approved agent (canagliflozin, dapagliflozin, empagliflozin or ertugliflozin)

T2DM patients aged 18 years or older, mean age 63.1-64.4 years. Patients had any established CVD, multiple CV risk factors and/or renal impairment

MACE

Median follow-up range 2.4-4.2 years

81

NC

UE 344

SGLT-2i in monotherapy or add-on therapy with any approved agent (canagliflozin, dapagliflozin, empagliflozin or ertugliflozin)

T2DM patients aged 18 years or older, mean age 63.1-64.4 years. Patients had any established CVD, multiple CV risk factors and/or renal impairment

Hospitalisation for HF

Median follow-up range 2.4-4.2 years

32

NC

UE 344

SGLT-2i in monotherapy or add-on therapy with any approved agent (canagliflozin, dapagliflozin, empagliflozin or ertugliflozin)

T2DM patients aged 18 years or older, mean age 63.1-64.4 years. Patients had any established CVD, multiple CV risk factors and/or renal impairment

Composite renal outcome

Median follow-up range 2.4-4.2 years

20

NC

UE 344

SGLT-2i and metformin

People with T2DM taking metformin

Developing 3P-MACE

Mean 3.2 years

63

202

NE 339

SGLT-2i and metformin

People with T2DM taking metformin

CV death

Mean 3.2 years

67

214

NE 339

SGLT-2i and metformin

People with T2DM taking metformin

All-cause mortality

Mean 3.2 years

50

160

NE 339

SGLT-2i and metformin

People with T2DM taking metformin

Hospitalisation for HF

Mean 3.2 years

32

102

NE 339

SGLT-2i and metformin

People with T2DM taking metformin

Non-fatal stroke

Mean 3.2 years

250

800

NE 339

SGLT-2i and metformin

People with T2DM taking metformin

Renal composite outcome

Mean 3.2 years

29

93

NE 339

SGLT-2i and metformin

People with T2DM taking metformin

End-stage renal disease

Mean 3.2 years

112

358

NE 339

SGLT-2i and metformin

People with T2DM taking metformin

AKI

Mean 3.2 years

112

358

NE 339

SGLT-2i and metformin

People with T2DM taking metformin

Doubling of serum creatinine

Mean 3.2 years

46

147

NE 339

SGLT-2i and metformin

People with T2DM taking metformin

Decline in eGFR

Mean 3.2 years

50

160

NE 339

Sulfonylureas

People with T2DM taking metformin

Risk of renal composite outcome

Mean 3.2 years

91

291

NE 339

Sulfonylureas

People with T2DM taking metformin

Risk of microalbuminuria

Mean 3.2 years

56

179

NE 339

Sulfonylureas

People with T2DM taking metformin

Progression of albuminuria

Mean 3.2 years

56

179

NE 339

Sulfonylureas

People with T2DM taking metformin

End-stage renal disease

Mean 3.2 years

334

1069

NE 339

Sulfonylureas

People with T2DM taking metformin

Risk of developing macro albuminuria

Mean 3.2 years

84

269

NE 339

Intensive sulfonylureas with insulin to achieve fasting plasma glucose less than 6.0mmol/L

Adults 25-65, with newly diagnosed T2DM

Any diabetes end point

10 years (median follow-up)

20

200

PG ^[345]

Intensive sulfonylureas with insulin to achieve fasting plasma glucose less than 6.0mmol/L

Adults 25-65, with newly diagnosed T2DM

Diabetes related death

10 years (median follow-up)

91

910

PG 345

Intensive sulfonylureas with insulin to achieve fasting plasma glucose less than 6.0mmol/L

Adults 25-65, with newly diagnosed T2DM

Micro-vascular complications

10 years (median follow-up)

36

260

PG 345

Metformin to achieve fasting blood glucose <6.0mmol/L (maximum dose 2550mg)

Glibenclamide added if target not achieved and changed to insulin if required

Newly diagnosed T2DM patients, mean age 53 years (25-65); mean weight 87kg; BMI 31, FPG above 6.0 mmol/L.

Overweight defined as >120% ideal body weight

Any diabetes end point

10.7 years (median follow-up)

7

80

PG ^[346]

Metformin to achieve fasting blood glucose <6.0mmol/L (maximum dose 2550mg)

Glibenclamide added if target not achieved and changed to insulin if required

Newly diagnosed T2DM patients, mean age 53 years (25-65); mean weight 87kg; BMI 31, FPG above 6.0 mmol/L.

Overweight defined as >120% ideal body weight

Diabetes related death

10.7 years (median follow-up)

19

203

PG 346

Metformin to achieve fasting blood glucose <6.0mmol/L (maximum dose 2550mg)

Glibenclamide added if target not achieved and changed to insulin if required

Newly diagnosed T2DM patients, mean age 53 years (25-65); mean weight 87kg; BMI 31, FPG above 6.0 mmol/L.

Overweight defined as >120% ideal body weight

Microvascular disease

10.7 years (median follow-up)

45

481

PG 346

Intensive control of glucose by including Gliclazide mr to existing medication to achieve a HbA1c of 6.5% or less

Patients with T2DM at least 55 years old with major macro- or micro-vascular disease or at least one other risk factor for vascular disease

Major microvascular or macrovascular events (death from CV causes, nonfatal MI, or nonfatal stroke)

5 years median

53

263

PG ^[347]

Intensive control of glucose by including Gliclazide mr to existing medication to achieve a HbA1c of 6.5% or less

Patients with T2DM at least 55 years old with major macro- or micro-vascular disease or at least one other risk factor for vascular disease

Major micro-vascular events (new or worsening nephropathy or retinopathy)

5 years median

67

333

PG 347

RAAS Inhibitor

People with diabetes

MI

Mean 3.7 years

63

233

UE ^[348]

ACEIs (-pril)

People with diabetes

MI

Mean 3.7 years

62

229

UE 348

RAAS Inhibitor

People with diabetes

HF

Mean 3.7 years

52

192

UE 348

ACEIs (-pril)

People with diabetes

HF

Mean 3.7 years

78

89

UE 348

ARBs

People with diabetes

HF

Mean 3.7 years

24

289

UE 348

RAAS Inhibitor

People with diabetes

All-cause mortality

Mean 3.7 years

106

392

UE 348

ACEIs (-pril)

People with diabetes

All-cause mortality

Mean 3.7 years

48

178

UE 348

Bisphosphonate (Risedronate)

Postmenopausal women with fracture risks, but not with osteoporosis caused by underlying disease or medication. Divided by primary prevention (lower risk of osteoporotic fracture) and secondary (higher risk)

Non-vertebral fractures assessed with: radiographic methods or participant's clinical signs and symptoms

1-3 years

50

NC

UE 309

Bisphosphonate (Risedronate)

As above

Hip fractures assessed with: Radiographic methods or participant's clinical signs and symptoms

1-3 years

127

NC

UE 309

Risedronate 5mg/day

As above

Five-year risk of non-vertebral fracture

1-3 years

58

NC

UE 309

Risedronate 5mg/day

As above

Five-year risk of non-vertebral fracture

1-3 years

38

NC

UE 309

Risedronate 5mg/day

As above

Five-year risk of non-vertebral fracture

1-3 years

30

NC

UE 309

Risedronate 5mg/day

As above

Five-year risk of non-vertebral fracture

1-3 years

25

NC

UE 309

Risedronate 5mg/day

As above

Five-year risk of non-vertebral fracture

1-3 years

18

NC

UE 309

Risedronate 5mg/day

As above

Five-year risk of hip fracture

1-3 years

926

NC

UE 309

Risedronate 5mg/day

As above

Five-year risk of hip fracture

1-3 years

412

NC

UE 309

Risedronate 5mg/day

As above

Five-year risk of hip fracture

1-3 years

195

NC

UE 309

Risedronate 5mg/day

As above

Five-year risk of hip fracture

1-3 years

95

NC

UE 309

Risedronate 5mg/day

As above

Five-year risk of hip fracture

1-3 years

43

NC

UE 309

Risedronate 5mg/day

As above

Five-year risk of radiographic vertebral fracture

1-3 years

214

NC

UE 309

Risedronate 5mg/day

As above

Five-year risk of radiographic vertebral fracture

1-3 years

103

NC

UE 309

Risedronate 5mg/day

As above

Five-year risk of radiographic vertebral fracture

1-3 years

48

NC

UE 309

Risedronate 5mg/day

As above

Five-year risk of radiographic vertebral fracture

1-3 years

36

NC

UE 309

Risedronate 5mg/day

As above

Five-year risk of radiographic vertebral fracture

1-3 years

23

NC

UE 309

Risedronate 2.5mg/day

As above

Five-year risk of radiographic vertebral fracture

1-3 years

225

NC

UE 309

Risedronate 2.5mg/day

As above

Five-year risk of radiographic vertebral fracture

1-3 years

108

NC

UE 309

Risedronate 2.5mg/day

As above

Five-year risk of radiographic vertebral fracture

1-3 years

51

NC

UE 309

Risedronate 2.5mg/day

As above

Five-year risk of radiographic vertebral fracture

1-3 years

38

NC

UE 309

Risedronate 2.5mg/day

As above

Five-year risk of radiographic vertebral fracture

1-3 years

24

NC

UE 309

Paracetamol

All adults (18 years and older) with diagnosis of primary OA (cause unknown), or secondary OA (cause known) at any site

Overall pain

Follow-up 1-12 weeks

16

Nrel

UE

^[349]

Paracetamol

All adults (18 years and older) with diagnosis of primary OA (cause unknown), or secondary OA (cause known) at any site

Pain response

6 weeks

4

Nrel

UE 349

Paracetamol

All adults (18 years and older) with diagnosis of primary OA (cause unknown), or secondary OA (cause known) at any site

Pain on Motion

6 weeks

5

Nrel

UE 349

Paracetamol

All adults (18 years and older) with diagnosis of primary OA (cause unknown), or secondary OA (cause known) at any site

Physician Global Assessment

6 weeks

2

Nrel

UE 349

Paracetamol

All adults (18 years and older) with diagnosis of primary OA (cause unknown), or secondary OA (cause known) at any site

Patient Global Evaluation

6 weeks

2

Nrel

UE 349

Aspirin 1000mg

Adults (18 years or older) with episodic and not chronic tension-type headache

Pain free or not

24 hours

NR

NC

UE

^[350]

Aspirin 1000mg

Adults (18 years or older) with episodic and not chronic tension-type headache

Use of rescue medication

NR

6

NC

UE 350

Aspirin 1000mg

Adults (18 years or older) with episodic and not chronic tension-type headache

Patient Global Evaluation

NR

6

NC

UE 350